NASDAQ:OGIOrganiGram Stock Price, Forecast & News

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OGI stock has decreased by 5.8% and is now trading at $1.62. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for OrganiGram.

OrganiGram is scheduled to release its next quarterly earnings announcement on Monday, July 20th 2020. View our earnings forecast for OrganiGram.

OrganiGram Holdings Inc (NASDAQ:OGI) announced its quarterly earnings data on Tuesday, April, 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.01. The firm had revenue of $27.30 million for the quarter, compared to the consensus estimate of $25.07 million. OrganiGram had a negative net margin of 45.14% and a negative return on equity of 5.33%. OrganiGram's revenue was down 18.3% compared to the same quarter last year. View OrganiGram's earnings history.

12 analysts have issued 1 year price objectives for OrganiGram's stock. Their forecasts range from $1.72 to $12.00. On average, they anticipate OrganiGram's stock price to reach $6.46 in the next year. This suggests a possible upside of 298.9% from the stock's current price. View analysts' price targets for OrganiGram.

News headlines about OGI stock have trended negative this week, InfoTrie reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OrganiGram earned a news impact score of -2.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an impact on the stock's share price in the next several days. View the latest news about OrganiGram.

Some companies that are related to OrganiGram include Athenex (ATNX), Arcus Biosciences (RCUS), Aimmune Therapeutics (AIMT), Phibro Animal Health (PAHC), BioXcel Therapeutics (BTAI), Amphastar Pharmaceuticals (AMPH), Legend Biotech (PLRX), Enanta Pharmaceuticals (ENTA), Rhythm Pharmaceuticals (RYTM), Nabriva Therapeutics (NBRV), Akero Therapeutics (AKRO), Arcturus Therapeutics (ARCT), Phathom Pharmaceuticals (PHAT), Retrophin (RTRX) and Gossamer Bio (GOSS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), KushCo (KSHB), Aphria (APHA), Auxly Cannabis Group (CBWTF), Charlotte's Web (CWBHF), Innovative Industrial Properties (IIPR), NVIDIA (NVDA) and Alibaba Group (BABA).

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OGI stock can currently be purchased for approximately $1.62.

OrganiGram has a market capitalization of $284.63 million and generates $61.27 million in revenue each year. The company earns $-7,200,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. OrganiGram employs 615 workers across the globe.

The official website for OrganiGram is www.organigram.ca.

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.